Recap: Day one of 2012 Thoracic SymposiumThe 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology kicked off yesterday with more than 750 in attendance. |


Recap: Day one of 2012 Thoracic SymposiumThe 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology kicked off yesterday with more than 750 in attendance. |

Lawrence Marks, MD, to give symposium's second keynote address todayToday at 10:00 a.m., Lawrence B. Marks, MD, the Dr. Sidney K. Simon Distinguished Professor of Oncology Research and chairman of radiation oncology at the University of North Carolina in Chapel Hill, N.C., will give his keynote address, "Evolution of Novel Radiation Strategies to Improve Therapeutic Index." The session will be moderated by Laurie E. Gaspar, MD, MBA, chairman of radiation oncology at the University of Colorado Denver in Aurora, Colo. |

Standard chemotherapy treatment provides equivalent survival rate to experimental regimen in late-stage lung cancer patientsTreatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research being presented today.Read more >>> |

Adding bavituximab to second-line chemotherapy doubles response rate in late-stage lung cancer patientsAdding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research being presented today. |

Plenary Session highlights top meeting scienceThe Plenary Session at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology is marked by several new presentations centering on the role of targeted agents in advanced non-small cell lung cancer, as well as updates of trials recently presented. |
10:00 a.m. - 10:30 a.m.
Grand Ballroom I-III
General Session V: Keynote II - Evolution of Novel Radiation Strategies to Improve Therapeutic Index
10:30 a.m. - 11:30 a.m.
Grand Ballroom I-III
General Session VI: Lung Cancer Screening – One Year Later - Where Are We?
12:30 p.m. - 2:40 p.m.
Grand Ballroom I-III
Plenary Session